This is the authors' abstract. We don't add key points for this paper.
Macrophages incubated with OVA in the presence of TGF-β2 induce immune deviation in vivo (impaired delayed hypersensitivity and IgG2a Ab production) when injected into naive, syngeneic mice. OVA-specific TCR transgenic naive T cells (DO11.10 T cells) produce Th1-type cytokines when stimulated in vitro with OVA-pulsed peritoneal exudate cells (PEC), but if PEC are first treated with TGF-β2 and then pulsed with OVA, the T cells secrete Th2-type cytokines instead. In this study, we investigated the mechanisms that are involved in the modified Ag-presenting functions of macrophages by TGF-β2 pretreatment. We have found that: 1) TGF-β2 impaired the capacity of PEC to produce IL-12 and to express CD40; 2) reduced CD40 expression on TGF-β2-treated PEC impaired IL-12 production when the cells were cocultured with DO11.10 T cells; 3) the failure of TGF-β2-treated PEC to stimulate DO11.10 T cells to secrete IFN-γ was due to their impaired IL-12 production. From these results, we conclude that TGF-β2 treatment impairs the ability of macrophages to produce IL-12 and to express CD40. As a consequence, TGF-β2-treated PEC fail to promote development of pT cells toward the Th1 phenotype.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Takeuchi et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: